Rapport Therapeutics (NASDAQ:RAPP) Shares Down 6.9% – Here’s Why

Rapport Therapeutics (NASDAQ:RAPP) was down 6.9% during mid-day trading on Friday . The stock traded as low as $15.07 and last traded at $15.54. Approximately 33,377 shares were traded during trading, a decline of 52% from the average daily volume of 69,255 shares. The stock had previously closed at $16.69.

Rapport Therapeutics Stock Performance

The stock’s 50 day simple moving average is $20.85.

Institutional Investors Weigh In On Rapport Therapeutics

Hedge funds have recently modified their holdings of the business. Values First Advisors Inc. acquired a new stake in Rapport Therapeutics in the 3rd quarter worth $31,000. BNP Paribas Financial Markets bought a new stake in shares of Rapport Therapeutics during the third quarter valued at approximately $34,000. JPMorgan Chase & Co. acquired a new position in shares of Rapport Therapeutics in the third quarter valued at $83,000. SG Americas Securities LLC acquired a new stake in Rapport Therapeutics during the third quarter worth $101,000. Finally, Sandia Investment Management LP bought a new position in shares of Rapport Therapeutics during the 2nd quarter worth about $116,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.